Cantor Fitzgerald’s Viking Therapeutics VKTX Stock Holding History

Cantor Fitzgerald’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-86,698	Closed	-$2.3M	–	548
2025 Q2	$2.3M	Buy	+86,698	New	+$2.28M	0.04%	101
2025 Q1	–	Sell	-9,450	Closed	-$380K	–	396
2024 Q4	$380K	Buy	+9,450	New	+$539K	0.01%	140

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cantor Fitzgerald's VKTX Position: Q3 2025 in Review

Cantor Fitzgerald sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 86,698 shares — an estimated $2.3M sold.

Cantor Fitzgerald first reported a position in VKTX in Q4 2024 and held it in 2 quarters. The position peaked at $2.3M in Q2 2025. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Cantor Fitzgerald reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
Cantor Fitzgerald sold 86,698 Viking Therapeutics shares in Q3 2025, an estimated $2.3M.
Cantor Fitzgerald first reported a position in Viking Therapeutics in Q4 2024 and held it in 2 quarters.
Cantor Fitzgerald's Viking Therapeutics position peaked at $2.3M in Q2 2025.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.